Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Protara Therapeutics, Inc.

NASDAQ: TARA · Life Sciences · 2 alerts · CIK 1359931

Share price
$2.38Close, Nov 16
Market cap
$147M
Shares outstanding
61.57MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Protara Therapeutics, Inc. filings on SEC EDGAR ↗

8:11 AM ET 10-Q
Financial Results

Protara Therapeutics Q3 2026 Results: Net Loss of $21.7M, Loss Widens

Protara Therapeutics reported a net loss of $61.1 million for the nine months ended September 30, 2026, compared to a $40.1 million loss in the prior year, driven primarily by a significant increase in research and development expenses. As of September 30, 2026, the company maintained $127.1 million in cash, cash equivalents, and marketable debt securities to fund its clinical pipeline, including TARA-002 and IV Choline Chloride.

Key figure
Net loss $21.7M
8:06 AM ET 8-K
Financial Results

Protara Therapeutics Financial Results

Protara Therapeutics reported third quarter 2026 financial results and provided a clinical pipeline update, including the expected completion of enrollment for its TARA-002 registrational cohort in NMIBC by year-end. The company also announced an $8.75 million asset purchase agreement with Novex Innovations for manufacturing-related assets and reported a cash position of $143 million, sufficient to fund operations into 2028.

“Protara continues to deliver across our late-stage portfolio, advancing each of our programs toward its next key clinical and regulatory milestone. This steady progress positions us to close out the year with strong momentum and sets the stage for an impactful 2027.”

Jesse Shefferman, Chief Executive Officer at Protara Therapeutics

“TARA-002 has the potential to be a preferred treatment option for patients with non-muscle invasive bladder cancer (NMIBC), and we are on track to complete enrollment of the BCG-Unresponsive registrational cohort by year-end, a key step toward bringing this therapy to patients.”

Jesse Shefferman, Chief Executive Officer at Protara Therapeutics

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.